Use of the Cyclops® by Parkinson’s patients

Use of the Cyclops® dry powder inhaler by patients with Parkinson’s disease after inhalation instruction

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON22676

Enrollment

Registered

2019-10-21

Start date

2020-01-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: - Diagnosed with Parkinson's disease by a nerologist; - At least 18 years of age; - Signed informed consent.

Exclusion criteria

Exclusion criteria: - Not able to understand inhalation instruction (within a maximum of 30 minuten). - Previously participated in the Parkinson DPI-1, DPI-2 or DPI-3 studie (prior knowledge of the inhalation maneuver); - Active pulmonary disease.

Design outcomes

Primary

Measure	Time frame
The main study parameter is to investigate whether Parkinson’s patients are able to reproduce an optimal inhalation technique for the Cyclops® inhaler by measuring the pressure drop (kPa), breath hold time (sec.) and inhaled volume (L) after first and second inhalation instruction.	—

Secondary

Measure	Time frame
The secondary study parameter is to investigate whether Parkinson’s patients perform the correct steps in accordance with the patient instruction card with the Cyclops® inhaler after first and second inhalation instruction.	—

Contacts

Public ContactA.F. Aalbers

Martini Ziekenhuis

a.aalbers@mzh.nl050-5245771

Outcome results